|
|
|
|
FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter
Main Category: / CardiologyAlso Included In: Article Date: 03 Jul 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the U.S.Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients...
|
|
|
FDA Approves Dronedarone for Atrial Fibrillation
_ FDA Approves Dronedarone for Atrial Fibrillation.
|
|
|
FDA Approves Dronedarone for Atrial Fibrillation
_ FDA Approves Dronedarone for Atrial Fibrillation.
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
- Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S.Food and...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
- Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S.Food and...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - - U.S.commercial launch planned for the summer of 2009 PARIS, July 2 (HSMN NewsFeed) -- Sanofi...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S.Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial...
|
|
|
FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter
Cardiovascular / Cardiology News Main Category: Cardiovascular / Cardiology Also Included In: Regulatory Affairs / Drug Approvals; Clinical Trials / Drug Trials; Pharma Industry / Biotech Industry email to a friend printer friendly view /...
|
|
|
FDA Approves Dronedarone for Atrial Fibrillation or Atrial Flutter
-- The US Food and Drug Administration (FDA) has approved dronedarone (Multaq) 400 mg tablets to reduce cardiovascular hospitalisation in patients with atrial fibrillation (AF) or atrial flutter (AFL).The approval was based on...
|
|
|
Sanofi: FDA approved atrial fibrillation drug Multaq, first new arrhythmia drug in a decade
TRENTON, N.J.(AP) - Sanofi-Aventis SA said Thursday its drug Multaq, which treats irregular heart rhythms, received marketing approval from the Food and Drug Administration, which turned it down three years ago. Multaq is intended to...
|
|
|
Sanofi-Aventis arrhythmia drug Multaq approved
TRENTON, N.J.(AP) - Sanofi-Aventis SA said Thursday its drug Multaq, which treats irregular heart rhythms, received marketing approval from the Food and Drug Administration, which turned it down three years ago. Multaq is intended to...
|
|
|
FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Fl
- Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter - U.S Commercial Launch Planned for the Summer of 2009 Sanofi-aventis (EURONEXT: SAN and NYSE:...
|
|
|
FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter
(PR Newswire Europe via COMTEX) -- SNY | Quote | Chart | News | PowerRating -- Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter - U.S Commercial...
|
|
|
FDA Approves Multaq for Patients With Atrial Fibrillation or Atrial Flutter
PARIS, July 2 /PRNewswire/ -- - Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter - U.S Commercial Launch Planned for the Summer of 2009 Sanofi...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
- Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S.Food and...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
- Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced...
|
|
|
FDA Approves Multaq for Patients with Atrial Fibrillation or Atrial Flutter
Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - - U.S.commercial launch planned for the summer of 2009 - PARIS, July 2 /PRNewswire-FirstCall/ --...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
- Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - - U.S.commercial launch planned for the summer of 2009 - PARIS, July 2 /PRNewswire-FirstCall/ -...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
- Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - - U.S.commercial launch planned for the summer of 2009 - PARIS, July 2 /PRNewswire-FirstCall/ -...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
--- Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - --- U.S.commercial launch planned for the summer of 2009 - PARIS, July 2, 2009 /PRNewswire...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
- Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - - U.S.commercial launch planned for the summer of 2009 - PARIS, July 2 /PRwire-FirstCall/ --...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Sponsored by: SCOTTRADE: Start trading for just $7 More News related to SAN More News related to SNY More News related to Press Releases PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S.Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S.Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial...
|
|
|
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S.Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial...
|
